Abivax CEO says $920M raise lets it launch its bowel disease drug in the U.S. solo
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
Overview
The French biotech plans to use proceeds to commercialize obefazimod in the U.S. through 2029, CEO Marc de Garidel told CNBC
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
